

## ArcticZymes Technologies ASA – Capital Markets Day 2026. Scaling a High-Performance Enzyme Platform for Compounding Growth

**Stockholm, 6 March 2026: ArcticZymes Technologies ASA (OSE: “AZT”) today hosts its Capital Markets Day 2026 in Stockholm, outlining how the Company is scaling a diversified enzyme platform designed to deliver sustainable growth and long-term value creation.**

Building on more than 30 years of enzyme expertise, ArcticZymes is positioned to benefit from increasing demand for high-performance enzymes used in molecular diagnostics, research and advanced biomanufacturing.

*“ArcticZymes is entering its next phase of growth. By strengthening our commercial engine, expanding our enzyme portfolio and embedding our technology deeper into customer workflows, we are building a scalable platform positioned to deliver compounding growth over time,”* says Michael Akoh, CEO of ArcticZymes Technologies.

### Investment case: A scalable enzyme platform

ArcticZymes’ strategy is built around a scalable enzyme platform with several structural advantages:

- **Embedded enzymes in regulated workflows**, creating recurring demand and high switching costs
- **Exposure to attractive life science markets**, including molecular diagnostics, viral vectors and RNA therapeutics
- **Scalable operating model**, where new enzymes leverage existing manufacturing, quality systems and commercial infrastructure
- **Strong balance sheet**, supporting continued investment in innovation and commercial expansion

Together these characteristics position ArcticZymes to generate **compounding growth with increasing operating leverage over time.**

### Strategic direction: a customer-centric and diversified platform

Over recent years, ArcticZymes has evolved its strategy from a product-focused enzyme supplier toward a **customer-centric platform company.** The strategy is built on two key pillars:

#### Customer-focused market approach

Transitioning toward solving defined workflow challenges across molecular research, diagnostics and bioprocessing.

#### Broader and more resilient business base

Diversifying customers, applications and workflows to strengthen growth durability and reduce concentration risk.

Within its two main segments - **Molecular Tools and Biomanufacturing** - ArcticZymes has expanded both its customer base and application footprint. Growth is expected to be supported

by new opportunities in areas such as **metagenomics**, as well as increasing the number of enzymes used within each customer workflow.

*“Our platform approach means we are not only adding customers we are becoming increasingly embedded in their workflows. This strengthens long-term relationships and expands recurring business as customers scale,”* adds Akoh.

### **Financial ambition: outgrowing served markets over time**

During the Capital Markets Day, ArcticZymes also presented its **long-term financial ambition**. The Company’s ambition is to **achieve sustainable double-digit revenue growth over time**, with the objective of **outgrowing the markets it serves as the enzyme platform continues to scale and diversify**.

As revenue grows, ArcticZymes expects to benefit from operating leverage driven by its largely fixed cost base and continued commercial execution.

### **Capital allocation priorities**

As of end of 2025, ArcticZymes held approximately **NOK 265 million in cash**, providing both financial resilience and strategic flexibility.

The **Company** prioritizes capital allocation toward high-return organic investments while maintaining optionality for disciplined value-accretive opportunities.

*“Our strong balance sheet enables us to invest where we see the highest long-term returns - through focused R&D, commercial expansion and selective value-accretive opportunities. With a scalable business model, organic growth investments can generate attractive compounding value creation,”* says Akoh.

### **CMD details**

The Capital Markets Day takes place in **Stockholm on 6 March 2026 from 09:00–12:00 CET**.

Alongside ArcticZymes management, customer representatives **Lee Davies (OXB)** and **Rafi Ahmad (University of Inland, Norway)** will present how ArcticZymes enzymes are used in real clinical and biomanufacturing workflows.

The event can be followed live via webcast:

<https://www.finwire.tv/webcast/arcticzymes-technologies/cmd/>

A replay will be available at

<https://www.arcticzymes.com/investors> following the presentation.

### **For further information**

**Børge Sørvoll**

Chief Financial Officer  
ArcticZymes Technologies ASA  
ir@arcticzymes.com  
+47 952 90 187

**About ArcticZymes Technologies ASA**

ArcticZymes Technologies ASA is a publicly listed biotechnology company headquartered in Tromsø, Norway. The company develops and manufactures high-performance enzymes used in molecular research, diagnostics and advanced biomanufacturing.

Inspired by enzymes found in Arctic organisms, ArcticZymes products are designed to perform under demanding process conditions, enabling improved efficiency, reliability and quality in critical life science workflows.

ArcticZymes is certified to ISO 13485 and manufactures according to relevant ICH GMP standards.

More information is available at [www.arcticzymes.com](http://www.arcticzymes.com)